Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hydroxyl carthamin yellow A in preparation of drugs for treating pyaemia

A technology of hydroxy safflower and yellow pigment, applied in the field of medicine, can solve the problems of putting specific drugs into clinical practice, etc.

Inactive Publication Date: 2019-03-01
TIANJIN CHASE SUN PHARM CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For many years, antibiotics, antiviral drugs, and vasopressor drugs have been used in the traditional treatment of sepsis, but there are not enough specific drugs targeting the pathogenesis of sepsis to be put into clinical practice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydroxyl carthamin yellow A in preparation of drugs for treating pyaemia
  • Application of hydroxyl carthamin yellow A in preparation of drugs for treating pyaemia
  • Application of hydroxyl carthamin yellow A in preparation of drugs for treating pyaemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1 Hydroxysafflower yellow A mouse intravenous administration acute toxicity test

[0030] 1. Experimental materials

[0031] Clean grade SD rats (half male and half female), 180-220g, hydroxysafflor yellow A, physiological saline (0.9% sodium chloride injection).

[0032] 2. Experimental method

[0033] 40 animals (half male and half male) were screened according to animal weight gain, diet, and activity during the adaptation period to enter this experiment, and were divided into 2 groups by weight block method, with 20 animals in each group, half male and half male. The maximum dosage method was used in the experiment, the maximum concentration of hydroxysafflower yellow A was 50mg / mL, and the intravenous injection limit for rats was 6mL / kg. In summary, the maximum dosage was 300mg / kg. The experimental group was given a single administration, 6 mL / kg hydroxysafflower yellow A liquid (50 mg / mL), and slowly injected intravenously; the control group was given...

Embodiment 2

[0038] Example 2. Evaluation of the effect of hydroxysafflor yellow A on the release of HMGB1 from rat peritoneal macrophages stimulated by LPS

[0039] 1. Experimental materials

[0040] Male clean grade SD rats, 180-220g, endotoxin (LPS), hydroxysafflor yellow A, RPMI-1640 medium, 24-well plate, HMGB1ELISA kit.

[0041] 2. Experimental method

[0042]Isolate peritoneal macrophages of male SD rats (male SD rats were fasted for 12 hours before operation, opened the abdominal cavity after anesthesia, injected 10 mL of pre-cooled PBS solution into the abdominal cavity, and rubbed the abdominal wall with fingers to make the liquid flow in the abdominal cavity. Inject the liquid in the sterilized tube, and then lavage once with 10mL of pre-cooled PBS solution, the operation is the same as above. Centrifuge 250g of the combined lavage fluid at 4°C for 10min, discard the supernatant. Add 2mL of erythrocyte lysate to dissolve the erythrocytes, Slightly oscillate twice, 5s each time...

Embodiment 3

[0050] Example 3. Evaluation of the effect of hydroxysafflower yellow A on the release of TF and PAF from rat abdominal aortic endothelial cells stimulated by LPS

[0051] 1. Experimental materials

[0052] Male clean grade SD rats, 180-220g, LPS, hydroxysafflor yellow A, ECM medium, 24-well plate, tissue factor (TF) ELISA kit, platelet activating factor (PAF) ELISA kit.

[0053] 2. Experimental method

[0054] After killing the rats by cervical dislocation, immerse them in 75% ethanol for 5 minutes, open the chest and abdominal cavity layer by layer, fully expose the thoracic and abdominal aortas, separate the surrounding tissues, and separate the aorta from the proximal end to the iliac The branches of the common artery were put into a petri dish containing PBS, the adipose tissue and fibrous tissue of the adventitia of the blood vessel were aseptically stripped, and the lumen of the blood vessel was washed with PBS. Cut the aorta into small pieces of about 1.5mm×1.5mm, pl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines and relates to new use of hydroxyl carthamin yellow A in treatment of pyaemia through inhibiting occurrence and development of the pyaemia. The invention particularly relates to application of the hydroxyl carthamin yellow A in treatment of the pyaemia through lowering expression of high-mobility group protein B1 (HMGB1) of late stage inflammatory factor, lowering release of tissue factor (TF) and platelet activating factor (PAF) and lowering expression levels of cytotoxin T lymphocyte related antigen 4 (CTLA-4) and fork head box protein transcription factor P3 (Foxp3) of regulatory T cells (Treg).

Description

Technical field: [0001] The invention belongs to the field of medicine and relates to a new therapeutic application of hydroxysafflor yellow A. technical background: [0002] Sepsis is a fatal organ dysfunction caused by an imbalanced host response to infection. The severe condition and high fatality rate are the main causes of death in critically ill patients. For many years, antibiotics, antiviral drugs, and vasopressor drugs have been used in the traditional treatment of sepsis, but there are not enough specific drugs targeting the pathogenesis of sepsis into clinical practice. How to timely correct the systemic inflammatory response, coagulation dysfunction and immune dysfunction during the occurrence and development of sepsis, restore the body's pro-inflammatory-anti-inflammatory dynamic balance as soon as possible, and effectively improve the prognosis of patients has become an urgent need in the research and development of sepsis drugs. important issues to be resolve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/351A61P29/00A61P31/00A61P7/04A61P37/02
CPCA61K9/0019A61K31/351A61P7/04A61P29/00A61P31/00A61P37/02
Inventor 李静远董凯董天皞姚咏明张桂萍王起运于洋王建立
Owner TIANJIN CHASE SUN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com